Cargando…

Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options

Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Ya-Ting, Lin, Chun-Yu, Chen, Yen-Hsu, Hsueh, Po-Ren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557615/
https://www.ncbi.nlm.nih.gov/pubmed/26388847
http://dx.doi.org/10.3389/fmicb.2015.00893
_version_ 1782388513650507776
author Chang, Ya-Ting
Lin, Chun-Yu
Chen, Yen-Hsu
Hsueh, Po-Ren
author_facet Chang, Ya-Ting
Lin, Chun-Yu
Chen, Yen-Hsu
Hsueh, Po-Ren
author_sort Chang, Ya-Ting
collection PubMed
description Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8–1.4% during 1997–2003 to 1.3–1.68% during 2007–2012. The most important molecular mechanisms contributing to its resistance to antibiotics include β-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism.
format Online
Article
Text
id pubmed-4557615
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-45576152015-09-18 Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options Chang, Ya-Ting Lin, Chun-Yu Chen, Yen-Hsu Hsueh, Po-Ren Front Microbiol Public Health Stenotrophomonas maltophilia is a Gram-negative, biofilm-forming bacterium. Although generally regarded as an organism of low virulence, S. maltophilia is an emerging multi-drug resistant opportunistic pathogen in hospital and community settings, especially among immunocompromised hosts. Risk factors associated with S. maltophilia infection include underlying malignancy, cystic fibrosis, corticosteroid or immunosuppressant therapy, the presence of an indwelling central venous catheter and exposure to broad spectrum antibiotics. In this review, we provide a synthesis of information on current global trends in S. maltophilia pathogenicity as well as updated information on the molecular mechanisms contributing to its resistance to an array of antimicrobial agents. The prevalence of S. maltophilia infection in the general population increased from 0.8–1.4% during 1997–2003 to 1.3–1.68% during 2007–2012. The most important molecular mechanisms contributing to its resistance to antibiotics include β-lactamase production, the expression of Qnr genes, and the presence of class 1 integrons and efflux pumps. Trimethoprim/sulfamethoxazole (TMP/SMX) is the antimicrobial drug of choice. Although a few studies have reported increased resistance to TMP/SMX, the majority of studies worldwide show that S. maltophilia continues to be highly susceptible. Drugs with historically good susceptibility results include ceftazidime, ticarcillin-clavulanate, and fluoroquinolones; however, a number of studies show an alarming trend in resistance to those agents. Tetracyclines such as tigecycline, minocycline, and doxycycline are also effective agents and consistently display good activity against S. maltophilia in various geographic regions and across different time periods. Combination therapies, novel agents, and aerosolized forms of antimicrobial drugs are currently being tested for their ability to treat infections caused by this multi-drug resistant organism. Frontiers Media S.A. 2015-09-02 /pmc/articles/PMC4557615/ /pubmed/26388847 http://dx.doi.org/10.3389/fmicb.2015.00893 Text en Copyright © 2015 Chang, Lin, Chen and Hsueh. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Chang, Ya-Ting
Lin, Chun-Yu
Chen, Yen-Hsu
Hsueh, Po-Ren
Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title_full Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title_fullStr Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title_full_unstemmed Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title_short Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
title_sort update on infections caused by stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4557615/
https://www.ncbi.nlm.nih.gov/pubmed/26388847
http://dx.doi.org/10.3389/fmicb.2015.00893
work_keys_str_mv AT changyating updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions
AT linchunyu updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions
AT chenyenhsu updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions
AT hsuehporen updateoninfectionscausedbystenotrophomonasmaltophiliawithparticularattentiontoresistancemechanismsandtherapeuticoptions